HROWHARROW, INC.
Pharmaceutical Preparations
- Revenue
- $272M
- 36% YoY
- Operating margin
- 11.2%
- 154% YoY
- EBITDA
- $32M
- 204% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- 6.7×
- $216M net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCClear5% of revenueOver 10% of revenue
- Payouts exceed cash flowClear-0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear0% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $72M | $89M | $130M | $200M | $272M | 36% |
| Operating income | $2M | $2M | $431K | $9M | $31M | 246% |
| Net income | −$18M | −$14M | −$24M | −$17M | −$5M | 71% |
| Operating cash flow | $5M | $2M | $4M | −$22M | $44M | 298% |
| Capex | $2M | $3M | $1M | $2M | $887K | 44% |
| Stock-based comp | $6M | $8M | $16M | $18M | $13M | 29% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $24M | $33M | 714 | 120 |
| FY2024 | $1M | $21M | 489 | 91 |
| FY2023 | $15M | $3M | 163 | 92 |
| FY2022 | $1M | $10M | 215 | 89 |
| FY2021 | $7M | $9M | 126 | 99 |